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Introduction:	High levels of inflammatory biochemical markers are associated with an increased 
risk among patients with acute coronary syndrome (ACS). The objective of the current study was to 
evaluate the prognostic significance of the systemic inflammatory response syndrome (SIRS) among 
ACS patients with no clinical or radiological evidence of congestive heart failure (CHF). 
Methods:	Consecutive patients with ACS and no clinical or radiological evidence of CHF in the 
emergency department (ED) were included in the study. The endpoint was hospital mortality. 
Categorical variables were compared by calculating proportions with 95% confidence intervals (CIs) 
and by using the Fisher Exact test. Continuous variables were compared by using the Wilcoxon 
Rank Sum test. The association of the variables with hospital mortality was assessed by using the 
logistic regression analysis.
Results:	The study included 196 patients (60 years; female 32.6 %). Six patients (3.1 %) died in 
hospital and 22 patients (11.2 %) had SIRS on admission to the ED. The following variables were 
predictors of hospital mortality: age with an odds ratio (OR) of 1.1 (95% CI, 1-1.2) for each one 
additional year (p <0.01), systolic arterial pressure with an OR 0.9 (95% CI, 0.9-1), diastolic arterial 
pressure with an OR 0.9 (95% CI, 0.8-1) for each one additional mmHg (p < 0.01), respiratory rate 
with an OR 1.5 (95% CI, 1.2-1.9) for each one additional breath per minute (p < 0.01), and SIRS with 
an OR 9 (95% CI, 1.7-47.8) (p 0.02). Because of the small number of events, it was not possible to 
assess the independence of these risk factors.
Conclusion:	SIRS was a marker of increased risk of hospital mortality among patients with ACS and 
no clinical or radiological evidence of CHF. [West J Emerg Med. 2010; 11(4):373-378.]
INTRODUCTION
There is increasing evidence supporting the pathogenic 
role of inflammation in acute coronary syndrome (ACS).1-4 
The local inflammatory process at the coronary artery plaque 
may cause the release of cytokines and other inflammatory 
acute-phase reactants into the circulation.5 Indeed, some 
evidence suggests that an independent systemic inflammatory 
process, apart from the local one, may also be involved in the 
pathogenesis of ACS.6 Clinical manifestation of systemic 
inflammation is known as systemic inflammatory response 
syndrome (SIRS), which may be seen in infections and a 
variety of other conditions.7,8 The diagnosis of SIRS is based 
on heart rate, respiratory rate, body temperature, and leukocyte 
count.7
Effective triaging of ACS patients is one of the main 
subjects of investigation in emergency medicine. One 
investigation line focuses on the subjacent inflammatory 
process as a prognostic factor. It has been demonstrated that 
high plasma levels of inflammatory biochemical markers are 
associated with an increased risk of major cardiac events in Western Journal of Emergency Medicine  374  Volume XI, no. 4  :  September 2010
ACS patients.5, 9–11 However, while these biochemical markers 
are not routinely available in the emergency department (ED), 
SIRS may be easily assessed in almost every ACS patient. We 
hypothesized that SIRS could be a prognostic marker among 
ACS patients. Since tachycardia and tachypnea, two of the 
diagnostic criteria of SIRS, are strongly associated with 
congestive heart failure (CHF), 12 we excluded ACS patients 
with clinical or radiological evidence of CHF.
The objective of the current study was to evaluate SIRS 
in the ED as a predictor of hospital mortality among ACS 
patients with no clinical or radiological signs of CHF.
METHODS
Study design
This prospective cohort study included ACS patients 
consecutively admitted to the ED between February 2003 
and January 2004. The study was approved by the local 
Institutional Research Board. The outcome was hospital 
mortality. 
Study setting and population
The study was conducted in an urban teaching hospital 
with 13 ED beds. The ED sees more than 86,000 patients per 
year. Consecutive patients aged more than 21 years old with 
confirmed diagnosis of ACS were enrolled in the study. All 
patients provided an informed consent. Patients with clinical 
or radiological signs of CHF were excluded from the study.
Study protocol
Medical history, physical exam, a 12-lead 
electrocardiogram, leukocyte count in peripheral blood and a 
chest radiograph were performed in every patient. The 
electrocardiogram was repeated in case of recurrent 
symptoms. Leukocytes were counted by using an automated 
cell counter as per standard laboratory techniques. Each 
patient had two or more determinations of plasma cardiac 
troponin I, one of them performed at least 12 hours after the 
onset of the symptoms. Cardiac troponin I concentrations were 
measured by chemiluminescence assay, using an ACS: 180 
automated analyzer (Bayer DiagnosticsTM) with a detection 
limit of 0.1 ng/ml and a cut-off value for myocardial necrosis 
of 0.5 ng/ml. Other diagnostic procedure and therapeutic 
strategies were decided by the medical team in charge of the 
patient. Data collection forms included medical history, 
clinical examination on admission to the ED and 
complementary tests (laboratory assays, stress test, myocardial 
perfusion test or coronary angiography) performed during 
hospitalization. 
SIRS was defined by the presence of at least two of the 
following criteria: 1) heart rate >90 beats/minute, 2) 
respiratory rate >20 breaths/minute, 3) body temperature 
>38°C or <36°C, and 4) leukocyte blood count >12 x 103/mm3 
or < 4 x 103/mm3.
The final diagnosis of acute myocardial infarction (AMI), 
unstable angina (UA), and CHF were independently assigned 
by two cardiologists based on the following definitions.
A final diagnosis of AMI was confirmed in the presence of 
two or more measurements of plasma cardiac troponin I above 
the cut-off value for myocardial necrosis (>0.5 ng/ml). 
A final diagnosis of UA was made in the presence of at 
least one of the following criteria: 1) two or more 
determinations of plasma cardiac troponin I within the range 
of myocardial injury (0.1 – 0.5 ng/ml), 2) ischemic 
abnormalities in at least two contiguous leads on the initial 
electrocardiogram (transient ST-segment depression ≥0.5 mm, 
transient ST-segment elevation ≥1 mm, or T-wave inversion 
≥2 mm), or 3) any evidence of severe coronary artery disease 
on complementary studies performed during hospitalization (a 
positive exercise stress test or cardiac perfusion test, or a 
coronary angiography demonstrating any severe stenosis in a 
major branch).
The diagnosis of CHF was based on physical exam 
reports (jugular venous distension, third sound, or pulmonary 
rales) and initial chest radiography (pulmonary edema). 
Echocardiography was not available in the ED.
In case of disagreement, a third cardiologist determined 
the final diagnosis. Inter-rater agreement was not evaluated.
Data analysis
On the basis of a previous report,13 120 patients were 
required to detect a 2.9% (95% confidence interval [CI], 
0-5.9%) of hospital mortality rate among ACS patients with 
no CHF on admission to the hospital.
Categorical variables were reported by using proportions 
and continuous variables by using medians and interquartile 
range (IR). Categorical variables were compared by 
calculating proportions with 95% CIs and by using the Fisher 
Exact test. Continuous variables were compared by using 
the Wilcoxon Rank Sum test. Abnormal values for body 
temperature and leukocyte count draw a U-shaped curve; 
therefore they were analyzed as dichotomized variables 
(“normal”/”abnormal”). The logistic regression analysis was 
used to determine how factors predicted hospital mortality. 
The odds ratios (ORs) for in-hospital mortality and the 
95% CIs were derived by using the asymptotic standard 
error of the estimate. Software package Excel™ version 
2000 (Microsoft™ Corporation, 1999) was used for data 
base management and Statistix™ version 7.0 (Analytical 
Software™) was used for all calculations. 
RESULTS
Description of the population
During the study period 255 ACS patients were evaluated 
in the ED. 59 (23.1%) patients had clinical or radiological 
signs of CHF and were excluded. The study population 
comprised of 196 patients (76.9%). Population characteristics 
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are shown in Table 1. The final diagnosis was AMI in 73 
patients (37.2%) and UA in 123 patients (62.8%).
Main results
Six patients (3.1%) died in hospital. The comparison 
between survivors and non-survivors is shown in Table 2. The 
variables age, systolic and diastolic blood pressure, ST-
segment elevation, and SIRS demonstrated a statistically 
significant difference between survivors and non-survivors. 
Because of the small number of events, it was not possible to 
assess the independence of these risk factors.14
22 patients (11.2%) had SIRS. The mortality rate was 
13.6% (95% CI, 0-28) among patients with SIRS and 1.7% 
(95% CI, 0-3.7) among patients without SIRS [risk ratio 
(RR) 7.9, 95% CI, 1.7-36.8] (p < 0.01). The AMI rate was not 
statistically different between both groups of patients: 40.9% 
(95% CI, 20.3-61.3) among patients with SIRS and 36.8% 
(95% CI, 29.6-43.9) among patients without SIRS (RR 1.1, 
95% CI, 0.6-1.9) (p 0.7). 
DISCUSSION
In the current study, ACS patients with SIRS on admission 
to the ED were at an increased risk of hospital mortality, 
compared with ACS patients without SIRS. SIRS was a 
predictor of mortality along with traditional risk factors, such 
as age, blood pressure, or ST-segment elevation. 
Inflammation plays a central role in the development of 
atherosclerosis and in the process of plaque rupture in ACS.15 
Acute phase reactants of inflammation may increase in 
plasma, which has been shown to provide prognostic 
information among ACS patients.16 
SIRS may be caused by the activation of the immune 
system8 in patients with an infectious disease;17-19 however, 
SIRS can develop in other non-infectious conditions, 
including traumatic injuries,20,21 critical surgeries,22,23 burns,20 
or pancreatitis.24 To our knowledge, the current study is the 
first to evaluate the prevalence and prognostic significance of 
SIRS among ACS patients. In a previous study, Rangel-
Frausto et al25 showed that the prevalence of SIRS in a general 
ED was 25 to 64%. In our study, only 11.2% of patients had 
SIRS. However, prevalence of SIRS in our study might have 
been higher if patients with CHF had not been excluded 
because tachycardia and tachypnea are common clinical 
manifestations in this condition.12 Rangel-Frausto el al 25 
reported that 32 to 64% of patients with SIRS developed 
sepsis during hospitalization. Patients in our study did not 
develop any infectious disease within 72 hours after admission 
to the hospital; therefore, infection did not appear to have been 
involved in the pathogenesis of SIRS among our patients.
ACS patients with SIRS were at an increased risk for hospital 
mortality. This finding is consistent with the findings of 
previous studies, which showed that SIRS was a marker 
of increased risk of death among patients with intestinal 
bleeding,18 critical surgeries23 and acute pancreatitis.24 
Two of the components of SIRS, tachycardia26-30 and high 
leukocyte count,31-33 are well-known markers of risk in ACS 
patients. 
In summary, SIRS may contribute to stratify the risk of 
ACS patients with no clinical or radiological signs of CHF in 
the ED.
LIMITATIONS
This study has important limitations. First, the standard 
definition of SIRS is strict and excludes patients with mild 
distortion of the inflammatory parameters.34 Moreover, the 
biochemical markers of inflammation other than leukocytes, 
such as C-reactive protein, fibrinogen, interleukin-6, tumor 
necrosis factor α may be more accurate for establishing an 
inflammatory state than the measurement of non-specific 
clinical parameters.8 However, the objective of this study was 
to evaluate the prognostic significance of classical SIRS, 
which may be easily determined in the ED setting.
Second, it could be hypothesized that tachypnea and 
tachycardia had been subtle signs of CHF, 12, 35 a marker of 
increased risk among ACS patients.13, 36-39 We could not strictly 
evaluate this hypothesis because other complementary studies, 
such as echocardiography or plasma B-type natriuretic 
factor,39 were not available in the ED. 
Table	1.	Baseline characteristics of 196 patients with acute coro-
nary syndrome and no clinical or radiological signs of congestive 
heart failure in the emergency department.
Continuous	variables Median IRQ
Age (years) 60 51-70
Categorical	variables N %
Demographic	data
Female  64 32.6
Medical	history
Hypertension
Diabetes mellitus
Cigarette smoking
Dyslipidemia
Coronary artery disease
Chronic stable angina
Myocardial infarction
Percutaneous coronary angioplasty
Coronary artery bypass surgery 
Stroke 
Peripheral artery disease 
124
21
118
52
84
49
41
20
13
7
12
63.3
10.7
60.2
26.5
42.9
25.0
20.9
10.2
6.60
3.60
6.10
Previous	treatment
Aspirin
Beta-blockers
Calcium-channel-blockers
Angiotensin converting enzyme inhibitors
Nitrates
Statins
Diuretics
66
64
25
54
34
9
14
33.7
32.6
12.8
27.6
17.4
4.60
7.10
IRQ, interquartile range
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Third, the increase in heart or respiratory rate may have 
been associated with fear or anxiety, 40 which are frequently 
triggered by pain.41 Consequently, it is possible to speculate 
that persistent chest pain, an ACS risk marker, 42 rather than 
inflammation was the cause of tachycardia and tachypnea in 
our study. However, in a clinical setting, Marco et al43 did not 
identify any significant association between pain score and 
Table	2. Comparison of baseline characteristics, emergency department variables and final diagnosis between non-survivors (n=6 
patients) and survivors (n=190 patients).
Non-survivors
(3.1%)
Survivors
(96.9%)
OR 95%	CI P
Continuous	variables	(median	[IQR])
Demographic	data
Age (years) 76 (67-80) 59 (51-69) 1.1 1-1.2 <0.01
Physical	exam
Systolic pressure (mmHg) 
Diastolic pressure (mmHg) 
Heart rate (beats/minute)
Respiratory rate (breaths/minute) 
Temperature (ºC) 
104 (93-117)
60 (46-68)
73 (60-107)
23 (22-28)
36.1 (36-36.2) 
130 (118-152)
80 (70-86)
71 (60-80)
20 (18-21)
36.2 (36-36.5) 
0.9
0.9
1
1.5
0.1
0.9-1
0.8-1
1-1.1
1.2-1.9
0-9.5
<0.01
<0.01
0.6
<0.01
0.3
Laboratory
Leukocyte count (x 103/mm3)  10.3 (7.9-13.8)  8.5 (7-11.3)  1 1-1 0.2
Categorical	variables	(%	[95%	CI])
Demographic	data
Female  50 (18.8-81.2) 32.1 (25.9-39.1) 2.1 0.4-10.8 0.4
Medical	history
Hypertension
Diabetes mellitus 
Cigarette smoking 
Dyslipidemia 
Coronary artery disease 
Chronic stable angina 
Myocardial infarction 
Percutaneous coronary angioplasty 
Coronary artery bypass surgery 
Stroke 
Peripheral artery disease 
66.7 (30-90.3)
0*
50 (18.8-81.2)
0*
16.7 (3-56.4)
16.7 (3-56.4)
16.7 (3-56.4)
0*
0*
0*
0*
63.2 (56.1-70)
11.1 (7.3-16.3)
60.5 (53.4-67.2)
27.4 (21.5-34.1)
43.7 (36.8-50.8)
25.3 (19.6-31.9)
21.1 (15.9-27.4)
10.5 (6.9-15.7)
6.8 (4-11.4)
3.7 (1.8-7.4)
6.3 (3.7-10.7) 
1.2
0
0.7
0
0.3
0.6
0.8
0
0
0
0
0.2-6.5
*
0.1-3.3
*
0-2.2
0.1-5.2
0.1-6.6
*
*
*
*
1
0.6
0.7
0.2
0.2
0.6
1
0.6
1
1
1
Electrocardiogram
Left bundle complete block 
Q waves 
Inverted T-waves 
ST-segment depression 
ST-segment elevation 
16.7 (3-56.4)
66.7 (30-90.3)
50 (18.8-81.2)
66.7 (30-90.3)
83.3 (43.7-97) 
3.2 (1.5-6.7) 
41.1 (34.3-48.2)
56.8 (49.7-63.9)
31.1 (24.9-38)
33.2 (26.9-40.1) 
6.1
2.9
0.8
4.4
10.1
0.6-60.9
0.5-16.1
0.1-3.9
0.8-24.9
1.2-88.1
0.2
0.4
1
0.09
0.02
Final	diagnosis
Acute myocardial infarction  83.3 (43.7-97)  35.8 (29.3-42.8)  9 1-78.4 0.03
Systemic	inflammatory	response
Systemic inflammatory response syndrome 
Increased heart rate 
Increased respiratory rate 
Abnormal temperature 
Abnormal leukocyte count 
50 (18.8-81.2)
33.3 (9.7-70)
83.3 (43.7-97)
0*
50 (18.8-81.2) 
10 (6.5-15.1)
10.5 (6.9-15.7)
24.7 (19.2-31.3)
0.5 (0.1-2.9)
21.6 (16.3-28) 
9
4.3
15.2
0*
3.6
1.7-47.8
0.7-24.7
1.7-133
*
0.7-18.7
0.02
0.1
<0.01
1
0.1
Continuous variables are reported by using medians and interquartile ranges (IQR) and compared by using the Wilcoxon Rank Sum test.
Categorical variables are reported by using percentages and 95% confidence intervals (CI) and compared by using the Fisher Exact test.
The odds ratios (ORs) were calculated by using bivariate logistic regression analyses.
*Exact confidence levels were not estimated because of zero count cells.
vital signs among more than 1000 ED patients, including 80 
with AMI. 
Fourth, the frequency of abnormal body temperature was 
low in our study (only one patient), despite the fact that fever 
has been described as a common finding after an AMI.44 
Previous studies45-48 reported serial body temperature 
determinations among AMI patients, while our study reported Volume XI, no. 4  :  September 2010  377  Western Journal of Emergency Medicine
only the first determination in the ED among patients across 
all ACS subsets. Gabriel et al49 attributed the fever to a 
systemic inflammatory response, a conclusion supported by 
the concomitant rise of acute phase reactants. 
Finally, the independence of the risk factors could not be 
assessed because the number of events was small.14 
CONCLUSION
The presence of SIRS on the admission to the ED was 
a marker of increased risk of hospital mortality among ACS 
patients with no clinical or radiological evidence of CHF.
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